[junkie-button url=”http://infomeddnews.com/” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]
The company reports that they intend to leverage Mediscan® for strengthening the commercial development and market penetration of its application portfolio in Asia and more specifically in China. Median also plans to focus on the commercial development of Mediscan® in Europe by leveraging its legacy hospital-based radiology customers, who were early adopters of its predecessor, LMS (Lesion Management Solution) product.
The recent opening of Median’s operations in Hong Kong, Tokyo and Shanghai, as well as the skyrocketing development of Median’s Boston-based subsidiary, will strengthen, re-engage and scale the KOL networks of the company for the Patient Care business lines, worldwide. Median intends to continue closely collaborate with FURUI, its Chinese investor and partner to help develop KOL networks and to develop medical partnerships with major hospital and cancer centers aiming at positioning MediScan® as the reference medical device for major programs dedicated to cancer screening, detection, diagnosis and monitoring in China.
Future releases of MediScan® include the integration of new technology based on the latest advances in artificial intelligence, cloud computing and Big Data analytics.
Jeanne Hecht, COO of Median Technologies said, “MediScan® is a critical part of Median’s commitment to improving care for patients worldwide. We believe that MediScan® fills a huge unmet need in helping governments and healthcare systems to efficiently and accurately screen, detect, help diagnose, and monitor patients at risk for and those living with cancer. It underscores Median’s core value of helping patients in need.”